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Summary 
1,5 deoxyspergualin (DSG) is a potent immunosuppressant whose mechanism of action is still 
somewhat of a mystery. We have studied the generation of lymphocytes in mice treated with 
this drug. The differentiation ofT cells in the thymus was blocked at an important early control 
point: the CD4-8-  --> CD4+8 + transition,  known to depend on the expression of a preTCR 
complex that includes  the variable  TCR-a3, but not TCR-o~, chain.  In clear contrast,  a later 
control point,  the  CD4+8 + ---> CD4+8-or CD4-8 + transition,  dependent  on the display of a 
conventional o~:~ TCR  complex, appeared unaffected, as did activation of mature T  cells both 
in vitro and in vivo. Interestingly, preB cell differentiation in the bone marrow was blocked at 
a precisely equivalent point: the A-C ---> C' transition, controlled by expression ofa pre-recep- 
tor complex containing the Ig heavy, but not light, chain. Mature B  cells seemed unperturbed. 
These  findings have theoretical  implications,  suggesting common signaling pathways in early 
lymphocytes that are distinct from those employed by more mature cells,  and are also of practi- 
cal interest,  to be considered in the design of DSG treatment protocols. 
R 
ecent  results  with  1,5  deoxyspergualin  (DSG) t  have 
aroused  considerable  interest  in  the  transplantation 
field (for review see reference 1). This drug, a synthetic deriv- 
ative  of the  antibiotic  spergualin,  is  a  potent  immunosup- 
pressant in a variety of contexts. It can prolong the survival 
of, even induce tolerance to, tissue grafts in several animal 
models.  These  include  transplants  of various organs in di- 
verse  donor-host  combinations,  involving  either  allo-  or 
xeno-disparities.  It  can  also  enhance  survival  of patients' 
tissue grafts, particularly renal transplants,  often those of an 
intransigent  nature.  DSG is frequently more effective than 
the popular immunosuppressants  cyclosporin A, FK506, or 
rapamycin,  and  routinely elicits  fewer side  effects.  There- 
fore, its use is presently being extended to chronic autoim- 
mune  diseases,  such  as  multiple  sclerosis  and  rheumatoid 
arthritis, which may require long-term administration. 
It is rather surprising,  then, that so little is known about 
the mechanism of action of DSG.  Several findings indicate 
that  it  operates  very  differently  from  the  cyclosporin  A 
family of drugs  (1,  2).  However, there  is no consensus on 
whether  its  immunosuppressant  properties  are  primarily 
due to effects on T  cells, B cells,  monocytes, or some corn- 
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RAG, recombination activating gene; HSA, heat stable antigen; FTOC, 
fetal thymic organ culture; DN, double negative (CD4-8-); SP, single 
positive (CD4+8 or CD4-8§  DP, double positive (CD4+8+); BCR, B 
cell receptor. 
bination of the three, perhaps varying in different contexts. 
Alterations  in  T  cell  proliferation  (3-6),  CTL  generation 
(4,  7, 8), B  cell maturation  (9),  Ab formation (9-12), anti- 
gen presentation (13), and cytokine production (12, 14-16) 
have all been described, but these reports are at times con- 
tradictory  and  are  difficult  to  assemble  into  a  consistent 
framework. 
The goal of our study was to evaluate the effect of DSG 
on the generation of lymphocytes, an important consider- 
ation for long-term treatment protocols. We began by ana- 
lyzing T  cell differentiation in the murine  thymus; the re- 
sults  obtained prompted us to perform a parallel analysis on 
B cell differentiation in the bone marrow. 
Materials and Methods 
Mice.  6-8-wk-old C57BL/6 (B6), Balb/c, DBA/2, and NOD/Lt 
mice  were  raised  in  our  specific  pathogen-free  animal  facility. 
Most experiments  were performed with B6 mice, but identical 
results were obtained with Balb/c, NOD, or DBA/2 animals. Mice 
deficient  for the  recombination  activating gene  (RAG)-2  (17) 
were obtained from Dr. H. Mossmann (Max  Planck Institut flir 
Immunbiologie, Freiburg,  Germany). 
DSG Administration.  Unless  stated  otherwise,  DSG was  dis- 
solved in PBS and administered  by intraperitoneal injections of 75 
p+g/adult mouse (3.75 mg/kg) body weight daily for different du- 
rations,  as indicated for individual  experiments in the figure leg- 
ends.  Lymphoid tissues were usually analyzed 24 h after the last 
injection. For treatment ofpreguant mice, 150 Ixg/d of DSG was 
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day 11 (the day of  discovery of the vaginal plug being termed em- 
bryonic day 0). Thymi were removed from embryos at day 16 or 
17 of gestation. 
Histological Analysis.  Mice were treated with DSG as described 
above. Thymi were excised after various injection protocols, fixed 
in Bouin's solution, and then embedded in paraffin. 5 p~m-thick 
sections were cut and stained with hematoxylin and eosin. 
CytofluorimetricAnalysis.  The  following  antibodies  and  re- 
agents  were  used  for  cell-surface staining:  anti-CD4  and  anti- 
CD8  (phycoerythrin-, fluorescein-, or biotin-conjugated; CAL- 
TAG  Labs.,  South  San  Francisco, CA);  anti-CD3  (KT3)  (18); 
anti-CD44  (1M7)  (19);  anti-B220  (RA3-6B2;  American Type 
Culture Collection, Rockville, MD [ATCC], reference 20); anti- 
HSA (M1/69;  ATCC,  reference 21);  anti-CD25  (7D4,  biotin), 
anti-Mac-1  (M1/70,  fluorescein), anti-c-kit (2B8  biotin), anti- 
CD43 ($7, phycoerythin), anti-CD69 (H1.2 F3, fluorescein; Phar- 
Mingen, San Diego, CA); and anti-mouse IgM (Texas-red-con- 
jugated; Jackson ImmunoResearch Labs., Inc., West Grove, PA). 
Cy5-conjugated streptavidin was used to reveal biotin-conjugated 
antibodies. 
Most thymocyte analyses were performed as described (22, 23). 
To distinguish subsets of CD4-8- cells by CD44 and CD25 expres- 
sion, three-color staining of thymocytes was performed essentially 
as described (24).  This involved staining with FITC-conjugated 
reagents against CD3, CD4, CD8, Mac-1 and CD45R (B220), and 
detecting CD44 and CD25 with Texas Red and PE, respectively. 
BrdU labeling and analysis has been described recently (25, 26). 
For the analysis of bone marrow cells,  single cell suspensions 
from femur and tibia were prepared by flushing with Dulbecco's 
modified Eagle's medium, followed by gentle pipetting in a small 
volume. To subdivide bone marrow cells of the B lineage, four- 
color staining was performed. Cells were first stained with anti- 
CD45R  supematant  on  ice  for  15  rain,  and  Cy-5-conjugated 
goat anti-rat IgG was used to reveal the first antibody. Free rat 
Ig-reactive sites were then blocked by normal rat serum, and the 
cells stained with anti-CD43 PE, anti-mouse IgM Texas red- and 
biotin-conjugated anti-HSA  (M1/69).  The  latter was  revealed 
with  FITC-conjugated streptavidin.  Cells were  analyzed on  a 
flow  cytometer  (Coulter  Corp.,  Hialeah,  FL);  fluorochromes 
were excited by the 488-nm line of an Argon laser (FITC and 
PE), and by the 600-rim line of a dye laser (Texas Red, Cy5). 
In Vitro Thymus Cultures.  Fetal thymus organ cultures (FTOC) 
were  performed basically as described (27).  Briefly, fetal thymi 
were obtained from day 14 B6  X  DBA/2 embryos, lobes were 
placed on Nucleopore filters (0.8 p~m; Costar Corp., Cambridge, 
MA) floating on 2 ml lscove's modified Dulbecco's medium with 
10%  heat-inactivated fetal bovine  serum  and  gentamicin at  50 
b~g/ml, and incubated at 37~  in 5% CO 2 humidified air atmo- 
sphere (28). DSG was added at 25  b~g/ml as indicated in the fig- 
ure legends. Cell suspensions were prepared from individual lobes 
and stained with anti-CD4 PE and anti-CD8 FITC. 
In Vivo Antibody Treatment.  Anti-CD3 ascites from the mAb KT3 
(18)  was  first  titrated on  RAG-2-deficient mice;  the  optimum 
condition was determined to be 50  p3 of ascites  injected intra- 
peritoneally. Experimental animals were  injected with KT3  as- 
cites plus or minus DSG (3.75 mg/kg) according to protocols de- 
tailed in the figure legends. 
For the studies on peripheral T cell activation, DSG-treated or 
control mice were injected with 50 p3 ofKT3 ascites and, lymph 
nodes were  taken 24  h  later. Single-cell suspensions were pre- 
pared and stained with anti-CD4-PE, anti-CD8-biotin and anti- 
CD69-FITC, followed by Cy5-conjugated streptavidin. 
Ex Vivo and In Vitro T Cell Proliferations.  For ex-vivo T cell pro- 
liferations, B6 mice were treated with DSG as described above for 
7 d. Single-cell suspensions were prepared from the spleens of these 
mice.  Various numbers  of cells were  stimulated with  5  p~g/ml 
ConA in 200  p~l RPMI-1640 medium supplemented with  10% 
FCS, antibiotics, 1 mM sodium pyruvate, glutamine, and 50 p~M 
2-ME in 96-well flat-bottomed plates. 1 p~Ci [3H]thymidine was 
added to each well in the last 8 h of a 36-h incubation, and up- 
take of label measured. All data points were in triplicate; standard 
deviations (not  shown)  were  consistently less  than  10%  of the 
mean. 
For the in vitro assay, 4  ￿  10  s spleen cells from untreated B6 
mice were stimulated with different concentrations of ConA, or 
of purified anti-CD3 antibody coated on 96-well flat-bottomed 
plates, in the presence of 0 or 25 wg/nd of DSG and 20 p~g/ml of 
aminoguanidine (13). After 24 h of culture, 1 I~Ci of [3H]thymi- 
dine was added and uptake of label measured. 
Results 
DSG Has Severe Effects on T  Cell Differentiation  in the Thy- 
mus.  We first focussed on the  effect of DSG  on  thymus 
architecture. B6 mice were injected daily with 3.75 mg/kg 
for varying times, thymi were removed 24 h after the last in- 
jection, and sections were cut and stained with hematoxy- 
lin/eosin.  As  illustrated  in  Fig.  1,  drug  treatment  pro- 
foundly perturbed  the  morphology of the  thymus,  nearly 
dissolving the cortical regions. This effect was first observed 
after 4  d  of injections (C)  and was  extreme after 8  d  (D). 
Interestingly, the  subcapsular region  could  still be  distin- 
guished even after the longest treatment time (D, arrow). The 
morphological perturbation was  fully reversible: after 8  d 
with treatment and then 10 d without, the cortex was fully 
regenerated and thymus architecture appeared normal (E). 
To  evaluate DSG  effects  on  differentiating T  cells, we 
performed  a  cytofluorimetric analysis  of thymocytes pre- 
pared  from  mice  injected  for  different  times.  Profiles  of 
anti-CD4 versus  anti-CD8  staining revealed a  progressive 
increase  in  the  proportion  of double-negative  (DN)  and 
single-positive (SP) cells at the expense of double-positives 
(DP)  (Fig. 2  A). Like the  changes in thymus  architecture, 
these alterations were fully reversible 10 d  after drug with- 
drawal (Fig. 2 A, right-most panels). The changing propor- 
tions of thymocyte subsets were mainly due to a drastic de- 
crease  in  the  number  of double-positive  cells  beginning 
after  2  d  of injections;  there  were  also  reductions  in  the 
three other compartments, but they were considerably less 
severe (Fig. 2 B). 
Reduced numbers of DP thymocytes are commonly ob- 
served with sick or otherwise stressed animals, a phenotype 
commonly  attributed  to  glucocorticoid-mediated apopto- 
sis. To rule out this and other indirect mechanisms for the 
DSG  effects,  we  studied  the  consequences  of  treating 
FTOCs  with this drug.  When  thymi were  removed from 
14-d-old fetuses and cultured for 8  d,  the last three in the 
presence of drug, they also showed a depletion of DP cells 
(Fig. 2  C). 
DSG Blocks the DN to DP Thymocyte  Transition.  The dras- 
tic  reduction  in  double-positive thymocytes provoked by 
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D), treated for 8 d and then rested for 10 (E), or treated with PBS only (A). Thymi were removed 24 d after the final injection, sectioned and stained with 
hematoxylin  and eosin, c, cortex; m, medulla; ssc, subcapsular cortex. 
DSG treatment might be explained by either (a)  a direct ef- 
fect on the DP  cells themselves or (b)  an indirect effect re- 
sulting from depletion of a  population  of precursor cells or 
from a block in their further maturation.  Certainly, the bulk 
of double-positive thymocytes was affected--both the small 
resting cells and the less mature blasts  (Fig. 3  A). Neverthe- 
less, the second explanation seemed more likely because we 
found that the number  of CD4-8 + CD3 l~ cells, the imme- 
diate precursors of the DP population,  was also severely re- 
duced in animals injected with the drug (Fig. 3  B). 
Focussing  one  step  further  back,  we  performed  a  more 
detailed cytofluofimetric analysis of the double-negative com- 
partment  in untreated versus DSG-treated mice. Many past 
studies  have  used  anti-CD44  and  anti-CD25  reagents  to 
characterize  DN  cells,  revealing the  following differentia- 
tion sequence: CD44+25 -  -0 CD44+25 + --~ CD44-25 + --~ 
Figure 2.  DSG preferentially affects immature  double-positive  thymocytes.  (A) B6 mice aged 6 
wk were treated with DSG (3.75 mg/kg body weight)  by daily injection (i.p.) for 1, 2, 3, 4, 5, 7, 
and 14 d. Thymocytes were harvested 24 h after the final injection, stained with anti-CD4 and anti- 
CD8 and analyzed by cytofluorimetry.  The proportion of double-positive  cells in the thymi of this 
representative  experiment is shown.  The left-most panel  shows the thymus  of a mouse injected 
with PBS only.  For the two right most panels, mice were injected with DSG for 14 d, treatment 
was discontinued  and the mice analyzed after another 5 or 10 d. (/3) Quantitation (expressed as total 
number of cells per thymus)  of the four thymic subpopulations,  gated as shown in A. DN: 4-8- 
double negatives. DP: 4+8 + double positives; CD4SP and CD8SP: CD4+CD8  - and CD4-CD8 + 
single positives, respectively. (C) Fetal thymi from day 14 embryos was cnltured in vitro at the air-medium interface for 8 d. DSG was added in some of 
the cultures  (right)  at the fifth day of culture,  a time at which substantial differentiation has occurred into the double-positive  compartment. 
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stage. A.  Mice  were treated with daily intraperitoneal  injection of DSG 
for 8 d, or with PBS only. Thymocytes were analyzed by three-color 
flow cytometry after staining  with anti-CD4, -CD8, and -CD3. In A, the 
histograms portray small double-positives and  double-positive blasts 
(gated on scatter profiles and on CD3 -/l~ phenotypes). The dot plots are 
standardized by total thymocyte number and display  an identical  propor- 
tion of the thymi (3 X 10-s), to illustrate  the DSG-induced depletion of 
both populations. (B) Anti-CD3 staining  histograms of gated CD4-CD8  + 
cells. The arrow highlights  the immature CD4-CD8+CD3  cells  whose 
loss is provoked by DSG. (C) Thymocytes  were labeled  with FITC-con- 
jugated anti-CD3, -CD4, -CD8, -CDllb, and -CD45RO (B220) and 
counterstained  with anti-CD44 (Texas Red) and anti CD25 (PE). Gated 
FITC-negative cells were analyzed for expression of CD44 and CD25. 
CD44/CD25 profiles of PBS-injected  mice (left) and DSG-treated mice 
(right) of representative experiment are shown. The histograms show the 
percentage of the three major subpopulations  of double-negatives,  gated 
as shown, in PBS injected mice (white bars) and DSG treated mice (black 
bars). Each bar represents an individual  animal. 
adult organ. Hence, we injected DSG daily into pregnant 
females starting on day  11  after fertilization and analyzed 
thymocytes on days 16 and 17.  The drug strongly blocked 
thymic development, preventing the rapid expansion ofthy- 
mocytes that normally occurs.  Only very rare  cells in the 
drug-treated mice differentiated to the DP stage:  on aver- 
age  only ,'-,0.1% of the normal numbers of CD4+8 +  cells 
were observed with thymi from day  17 fetuses taken from 
DSG-injected mothers (Fig. 4 D). The remaining DN pop- 
ulation was highly enriched in CD25 + cells (Fig. 4 s  It is 
possible that the block here is even more extreme than at 
first appreciated: many of the cells in the CD44-25- gate 
might actually be very immature, preCD44+25 -  recent im- 
migrants. 
The DN CD44-25 + stage is an important control point 
during thymocyte differentiation (for review see reference 
30).  At this stage,  the  preTCR complex is first expressed 
and this  event seems pivotal for further maturation: turn- 
offofTCR-~  gene rearrangement, turn-on of TCR-ot re- 
arrangement, population expansion and progression to the 
double-positive stage. Consequently, in mice which do not 
express the preTCR, for example those with a null muta- 
tion at  the  RAG locus, many fewer thymocytes are  pro- 
duced, and they are enriched in those at the DN CD44-25  + 
stage.  Recent experiments revealed that the  preTCR can 
be bypassed by crosslinking CD3 in vivo: injection ofanti- 
CD3e mAb into RAG-deficient animals provoked the tran- 
sit of a large number of cells into the double-positive com- 
partment (31-34).  Given our observation that DSG blocked 
thymocyte  differentiation  rather  specifically  at  the  DN 
CD44-25 + stage, we wondered whether it could influence 
the  artificial  transition  promoted  by  CD3  cross-linking. 
Thus,  we  injected  mAb  with  or  without  the  drug  into 
RAG-deficient animals and stained thymocytes after 3  d. 
Clearly,  DSG  inhibited  the  differentiation provoked  by 
anti-CD3e treatment, evident from a diminished DP popu- 
lation (Fig.  5  A,  upper panels)  and a reduced DN CD44-25- 
CD44-25-  (29).  As indicated in Fig. 3  C,  drug injection 
led to  a  reduction in the  proportion of the  most  mature 
DN subset, the CD44-25- cells.  This was due mostly to a 
decrease  in  their  number, but  there  were  also  slight  in- 
creases in the numbers of cells in the other subsets. 
A  block in differentiation might be more obvious with 
the quasi-synchronous cohort of thymocytes maturing in a 
fetal thymus than with the cells residing in the steady-state 
Figure 4.  DSG blocks differentiation  in the embryonic thymus. Preg- 
nant DBA/2 females (impregnated  by B6 males) were injected twice daily 
with DSG or PBS starting  at day 11 of gestation, and pooled thymi of the 
developing  embryos  were analyzed  at gestational  day 16 or 17 by cytoflu- 
orimetry. Total cell numbers per thymus (an average of 4 to 8 thymi) are 
shown on each panel. (A-D) CD4/CD8 staining;  (E) CD44/CD25 stain- 
ing of the DSG-treated day 17 sample. 
2430  Effects  of Deoxyspergualin on Thymus and Bone Marrow Lymphocytes subset  (Fig.  5 A, lower panels).  The drug could be added as 
late as 24 h  after the mAb and still inhibit the appearance of 
DP cells  (Fig. 5 B). 
DSG Does Not Inhibit the DP to SP Thymocyte  Transition, 
nor the Stimulation of Peripheral T  Cells.  A  second important 
control  point  during  thymocyte  differentiation  is  at  the 
transition  between  the  double-positive  and single-positive 
stages.  Positive  selection  into  the  CD4+8-and  CD4-8 + 
compartments involves specific recognition of MHC mole- 
cules on stromal cells  by the e~:~ TCR  on CD4+8 + T  cells 
(see  reference  35  for  review).  Positive  selection  can  be 
monitored by tagging replicating DNA in dividing imma- 
ture cells with a pulse of the thymidine analogue BrdU and 
following the flow of label  into  the mature  single-positive 
compartments.  It routinely  takes  ~3-5  d  before  label  in- 
corporated by dividing DP, immature  SP and DN precur- 
sors is detected to a significant degree in the population of 
mature  SP  cells  (23,  25,  36,  37).  As  indicated  in  Fig.  6, 
DSG did not influence  the flow of BrdU label into  either 
CD3  §  single-positive  compartment.  The  kinetics  and  de- 
gree of BrdU staining were indistinguishable  in control and 
DSG-treated mice. 
This result brought up  the issue  of whether  DSG influ- 
ences fully mature  peripheral  T  cells.  Total numbers  of T 
cells  in  spleen  and  lymph  node,  and  their  subpopulation 
distribution,  were  not  significantly  affected  (data  not 
shown).  As indicated in Fig.  7 A, the drug had little  effect 
Figure 5.  DSG blocks anti-CD3 induced differentiation  in the RAG  ~176 
thymus. (A) Knockout mice deficient  in the RAG-2 gene were injected 
once with anti-CD3 ascites to induce the bypass of the differentiative  block 
at the double-negative stage.  Control mice were injected with PBS only 
(left panels);  DSG (right panels)  was administered at -2, 0,  12, 24, and 36 h 
relative  to the anti-CD3 injection.  Thymi were analyzed  48  h  after  the 
injection of anti-CD3,  by staining with anti-CD4 and -CD8 (top panels), 
or with anti-CD44 and -25 (bottom panels).  (B) RAG-deficient mice were 
injected as in A, except that DSG treatment was initiated  either 4 h before 
or 24 h after the anti-CD3 treatment, and repeated every 12 h thereafter. 
Stainings  were performed 60 h after anti-CD3 injection. 
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Figure 6.  DSG does not impair selection into the mature single-posi- 
tive compartments. Cycling thymocytes  from B6 mice were pulse-labeled 
by injection of  BrdU. which was allowed to chase into the CD4+8  + dou- 
ble-positive compartment. The  flow of BrdU  label into  the  mature 
CD3+CD4+8  - and  CD3+CD4-8 + compartments was examined every 
day thereafter by cytofluorimetric  analysis. DSG treatment was applied in 
the last 48 h of the chase for each sample. The data shown here represent 
the percentage of BrdU-positive cells in the CD3+CD4+8  -  and CD3  § 
CD4-8  + single-positive compartments (CD4SP and  CDSSP, respec- 
tively) in DSG-treated or control mice. 
on  in vitro  T  cell proliferation provoked by anti-CD3  or 
ConA stimulation.  It seemed  more  relevant,  however,  to 
measure  the  reactivity  of peripheral  T  cells  from animals 
treated  under  the  conditions  which had  led  to  a block in 
differentiation  of immature  thymic T  cells.  Therefore,  we 
injected  DSG-treated  or  untreated  mice  with  anti-CD3e 
mAb (the same amount used for the experiments in Hg. 5) 
and evaluated the drug's effect on T  cell activation by moni- 
toring  expression  of the  early  activation  marker  CD69. 
DSG did not prevent T  cell activation by anti-CD3 in vivo 
(Fig. 7 B). Finally,  we assayed ex vivo the reactivity to anti- 
CD3  or  ConA  of  peripheral  lymphocytes  from  mice 
treated for 1 wk with the drug.  No impairment of reactiv- 
ity was detected (Fig. 7  C, and data not shown). 
Differentiation  of Immature B  Cells  Is Blocked  at an Equiva- 
lent Stage by DSG.  The differentiation of immature B  cells 
in  the bone marrow,  like that of T  cells  in the thymus, is 
strongly regulated  at  the  point where  the  first  of the  two 
variable  chains of the antigen receptor is expressed  (for re- 
view see  references  38  and  39).  This  control seems  to be 
exerted  through  a  preB  cell  receptor  (BCR)  that includes 
the variable Ig heavy chain and the invariable chains k5 and 
VpreB.  In mice that are unable to make one of these com- 
ponents,  for example RAG-deficient animals, B  cell matu- 
ration  is  arrested just  before  stages  characterized  by  rapid 
expansion  and  Ig light  chain rearrangement,  and few cells 
are exported from the bone marrow. 
Given the  above-described  effects on thymocyte differ- 
entiation  and the obvious parallels  between  early T  and B 
cell maturation, we explored the influence of  DSG on B cell 
differentiation.  Mice were injected with the drug for vari- 
ous lengths of time and, 24 h  after the last  treatment,  bone 
marrow cells were isolated  and analyzed by cytofluorime- 
try. The effects were quite dramatic.  First, drug administra- 
tion led to a depletion of cells  exhibiting the size character- 
istics of the lymphoid lineage, whereas granulocytes and other 
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Figure  7.  DSG does not grossly affect the reactivity of peripheral T 
cells. (A) Lymph node T cells from B6 mice were stimulated in vitro with 
anti-CD3 or ConA, as indicated, and the proliferative response measured 
24 h later as incorporation of [3H]thymidine. (/3) B6 mice were injected 
with anti-CD3 ascites as in Fig. 5, and CD69 expression on T cells (gated 
on CD4- or CD8-positive) was measured by cytofluorimetry. Control 
mice were injected with PBS only (left  panel); DSG (right panel) was ad- 
ministered at -2, 0, and 12 h relative to the anti-CD3 injection. (C). B6 
mice were treated for 1 wk with DSG (or PBS as control) and T cell reac- 
tivity was assessed by ConA stimulation in vitro. The proliferative re- 
sponse was measured 36 h later by incorporation of [3H]thymidine. 
large  myetoid  cells  appeared  unaffected  (Fig.  8  A).  The 
time course of depletion  paralleled  that for lymphoid cells 
in the thymus, significant reductions only becoming appar- 
ent after several days of treatment. 
Multiparameter  staining with reagents  specific for IgM, 
CD45R. (B220), CD43, and HSA allowed us to follow the 
fate of cells at different stages of B  cell differentiation.  The 
more  mature  subsets  are  illustrated  in  Fig.  8  B,  a  plot  of 
anti-B220 versus anti-IgM staining of cells gated as CD43- 
negative. DSG treatment gradually eliminated the preB and 
immature B  cell populations  (fractions D  and E  according 
to the nomenclature of Hardy and colleagues (38 and refer- 
ences therein),  but spared the most mature B  cells express- 
ing IgM and the highest levels orB220 (fraction F). Earlier 
B  cell subsets  are  depicted  in  the  top  panels  of Fig.  8  C, 
where  anti-B220  versus  CD43  staining  of IgM-negative 
cells  is  displayed.  The  preB  cells  of fraction  D  (B220 ++, 
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CD43  l~  were  completely  eliminated  after  12  d  of drug 
treatment,  but a substantial proportion of the proB cells in 
fractions A-C' remained.  These latter subsets were further 
separated  according to anti-HSA staining levels  (Fig.  8  C, 
bottom panels). Administration of DSG ehminated the more 
mature  cells with the  highest  HSA and B220 levels  (frac- 
tion C'), but appeared to spare fractions A-C. The patterns 
observed with bone marrow cells isolated from RAG-defi- 
cient mice and stained in parallel  were quite  similar,  with 
an  absence  of subsets  C'  and  D,  as  anticipated  (see  refer- 
ence  38  and references  therein).  The cells  which accumu- 
lated in RAG  ~176  mice did have a phenotype slightly differ- 
ent  from  those  which  remained  in  the  drug-treated 
animals, i.e., slightly higher B220 and HSA levels. 
Overall, the picture we observed for the B cell lineage in 
the bone marrow was strikingly reminiscent of that seen for 
the  T  lineage in the  thymus: DSG eliminated  the incom- 
pletely mature  populations  undergoing expansion  and se- 
lection,  but spared both the most immature and most ma- 
ture subsets.  Drug susceptibility appeared to coincide with 
expression of a pre-receptor composed of a single Ig or TCR. 
variable chain paired with an invariant surrogate partner. 
Discussion 
Our studies have explored the effect of DSG on the gen- 
eration of lymphocytes in the mouse. This drug interfered 
with the differentiation of early T  cell precursors in the thy- 
mus but not with the maturation/selection  nor the activa- 
tion of T  cells at later stages. It also blocked, in a quite par- 
allel manner, the differentiation of early B cell precursors in 
the  bone  marrow.  These  findings bear on two  important 
issues concerning lymphocyte development. 
Early- versus Late-Stage T  Ceils.  DSG blocked T  cell differ- 
entiation  at  an  early stage,  effectively and  precisely:  most 
DN  CD44-25 + cells did not mature  any further.  The  ef- 
fect was most obvious with thymus cells taken from fetuses 
exposed to the drug in utero  (Fig. 4  E), but was also clear 
with thymocytes from animals treated as young adults (Fig. 
3,  C  and  D).  In addition,  the  drug could block the  anti- 
CD3-induced  progression  of DN  cells  in  RAG  ~176  mice 
(Fig. 5 A). Quite in contrast, DSG did not have a measur- 
able  effect on late-stage  T  cells.  Positive  selection  of DP 
thymocytes into the SP compartments was unperturbed  in 
drug-treated animals  (Fig. 6), fully mature thymocytes and 
peripheral T  cells were spared (Fig. 2, A  and C and data not 
shown),  and  activation  of peripheral  T  cells by anti-CD3 
and ConA either in vitro or in vivo was unaffected (Fig. 7). 
One explanation for this dichotomy is that DSG inhibits 
signaling through the preTCR but not the conventional c~:[3 
TCR. Although no existing data establish that the preTCR 
complex, itself,  transduces signals during thymocyte differ- 
entiation, this would seem a hkely explanation for the con- 
trois on gene rearrangement, poptflation expansion and cell 
differentiation  exerted  in  coincidence  with  its  expression. 
Signal-transducing CD3 subunits are known to be compo- 
nents  of the  preTCR  complex,  and  it  has been  reported 
that the zeta chain binds more weakly than it does to the c~:[3 
Effects of  Deoxyspergualin  on Thymus and Bone Marrow Lymphocytes Figure  8.  DSG blocks B cell 
differentiation at  an early stage. 
BALB/c mice were treated with 
DSG  or  PBS  as  a  control  for 
varying times, as indicated. Bone 
marrow cells were analyzed by 
four-color  cytofluorimetry after 
staining  with  anti-IgM,  anti- 
CD45R (B220), anti-CD43, and 
anti-HSA.  (A)  Side vs  forward 
scatter two-dimensional profiles; 
the  granulocyte and  lymphoid 
populations are  shown on  the 
PBS panel. (B) Mature B cells are 
gated  as  CD43-negative,  and 
their  IgM/B220  profiles dis- 
played; populations D  (pre-B), 
E (immature B), and F (mature 
B), according to the nomencla- 
ture of  Hardy and colleagues (38) 
are indicated. (C) The pre- and 
pro-B stages of  differentiation are 
displayed after gating on  IgM- 
negative cells, to eliminate the B 
populations. Populations D (pre- 
B) and A-C' (pro-B) are shown 
on the top panels. The  CD43- 
positive cells, gated as shown, are 
further  resolved on  the  lower 
panels. 
TCR  complex (40), suggesting a possible basis for differen- 
tial signaling. Nonetheless,  in vitro experiments with trans- 
fected cell lines have not so far been able to distinguish sig- 
naling events set in motion by m_Ab engagement of the two 
receptors. As yet, only a few parameters have been investi- 
gated, however (40, 41).  On the other hand, in vivo or ex 
vivo experiments  with  mice have revealed differences be- 
tween the early and late control points in the thymus. Mice 
deficient  in  ZAP70  (42),  interferon  regulatory  factor 
(IRF)-I  (43),  and CD45  exon 6  (44)  all had defects in the 
DP  --> SP  transition,  mediated  by the  oL:[3 TCR,  but the 
DN  -->  DP  transition,  dependent  on  the  preTCR,  ap- 
peared  quite  normal.  Conversely,  tyrosine  kinase  inhibi- 
tors, such as herbimycin A, blocked the early transition but 
not the late one (28). 
It is also possible that the DSG effect on DN thymocytes 
is independent  of signaling through the pre-TCR.  Indeed, 
we did not observe any effect of the drug on pre-TCR sig- 
naling  elicited  in  vitro:  when  a  thymocyte  line  derived 
from a SCID mouse and transfected with the TCR-[3 gene 
(40)  was stimulated  with  anti-TCR-[5  or anti-CD3,  there 
was comparable Ca ++ mobilization and CD69 induction in 
the  presence  or  absence  of DSG  (data  not  shown).  One 
could question, however, how closely antibody stimulation 
of cultured  cells  in  vitro  mimics  receptor-ligand  interac- 
tions during thymocyte differentiation in vivo. Or it could 
be that any differences just lie further downstream. 
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Whichever explanation proves correct, one is left with the 
problem  of explaining  the  immunosuppressive  effects  of 
DSG in transplant and autoimmune situations,  which must 
ultimately depend on silencing mature T  cells in the periph- 
el i.  It is  possible  that  effects  on  mature  T  cell  activation 
more  subde  than  those  measured  by  ConA  or  anti-CD3 
stimulation are involved. It might also be that the immuno- 
suppressive  effects  are  more  indirect  involving,  for exam- 
ple,  antigen  presenting  cells.  This  has  been suggested in  a 
previous study (13) but we have not been able to find sup- 
port in similarly designed experiments  (data not shown). 
PreT and PreB Cell Eh'fferentiation.  DSG blocked T  cell dif- 
ferentiation at the stage where one of the variable receptor 
genes has been rearranged and its product displayed at the 
cell surface as part ofa pre-receptor complex. Expression of 
this preTCR is a prerequisite  for population expansion and 
further maturation.  DSG halted B  cell differentiation  at an 
equivalent stage, the (A-C)-->C' transition.  Progression be- 
yong the  (A-C)  stages  generally  requires  expression  of a 
pre-receptor composed of the Ig heavy chain and two non- 
variable chains, and is marked by a period of rapid ceil divi- 
sion  and  most  likely  some  kind  of cellular  selection  (38, 
39).  The  analogous blocks  in  B  and  T  cell  differentiation 
were  perhaps  most  evident  in  comparisons  with  RAG- 
deficient mice. These animals can not make the first recep- 
tor  variable  gene  rearrangement  and  thus  do  not  express 
either  a  preTCR  or  preBCR.  T  cell  differentiation  was blocked at a very similar stage in DSG-treated and RAG- 
deficient mice, as was B  cell differentiation.  The slight dif- 
ferences that were seen, particularly with B  ceils,  probably 
reflect the longer times of precursor accumulation in R_&G- 
deficient animals. 
What could be the root of this commonality? The sim- 
plest interpretation  again invokes signaling: there could be 
some shared element in signaling events associated with the 
"checking" of the preTCP,, and preBCR. No such element 
has so far been identified, but would not be surprising given 
the highly analogous scenarios which seem to be emerging. 
It  may be  relevant  that  DSG  was  found  to  inhibit  LPS- 
induced Ig K expression in the 70Z/3 preB cell lymphoma 
by reducing nuclear translocation of the transcription factor 
NF-KB (45)  and that anti-oxidant inhibitors of NF-KB ar- 
rested  0~:13 thymocyte  differentiation  at  the  DN  stage  in 
FTOC (46). It is thus conceivable that DSG interferes with 
the action of an NF-KB family member whose action is speci- 
fically required at parallel stages in B and T  differentiation. 
It is also possible that the DSG-sensitive event is not di- 
rectly  tied  to the  pre-receptor  complex.  We  think  it  un- 
likely that RAG-mediated gene rearrangements  are inhib- 
ited,  as  transgenics  expressing  prerearranged  TC1L  genes 
also  show  DSG-induced  loss of DP  thymocytes  (data  not 
shown).  Other  potential  targets  are  interactions  between 
adhesion  molecules  and  their  receptors  or  cytokines  and 
their  receptors.  Signals  emanating  from such  interactions 
might be required accompaniments for pre-receptor signals 
to effectively initiate or maintain the DN --+ DP transition. 
DSG could act directly on the immature T  cell precursor or 
could just  as  well  affect a  stromal  cell,  preventing it from 
delivering a signal essential  for T precursor maturation. IL-7/ 
IL-7R. and c-kit/stem cell factor interactions would at first 
seem attractive possibilities  because they are known to in- 
fluence both  B  and T  cell differentiation at an early stage. 
However,  ablation  of the  IL-7R gene,  treatment  in  vivo 
with an anti-IL-7 mAb and mutation of the c-kit locus all 
appear to block thymocyte differentiation at an earlier DN 
stage than DSG treatment does, after the CD44+25 -  rather 
than the CD44-25 + stage (47-49). Another possible target 
is CD81, a molecule expressed on thymic stromal cells and 
recently shown to be crucial during the DN -+ DP transi- 
tion (50). 
Finally,  the  leakiness  observed  with  DSG  treatment  of 
adult animals suggests a third possibility. Perhaps it is not so 
much differentiation  that is blocked as cell division.  Thus, 
there could be maturation from the A-C to C' stage for B 
cells,  or CD44-25 +  to  CD44-25-  for T  cells,  but  these 
products  would  remain  a  relatively  minor fraction  in  the 
absence  of the  massive  cell  expansion  that  normally takes 
place at this time. However, BrdU-labeling experiments did 
not support this interpretation: division of DP blasts and ma- 
ture  SP  cells  appeared  normal  in  mice  given  short-term 
DSG treatment  (data not shown).  Similarly,  cell prolifera- 
tion in vitro was not affected by DSG (Fig. 7  and data not 
shown).  In addition,  injection of mice in utero with DSG 
led  to  a  much  cleaner  phenotype,  only very few  cells,  if 
any, escaped the block at the DN CD44-25 § stage. 
Practical Implications.  Whatever  the  explanation  for the 
DSG-induced block and its commonality, our observations 
have practical implications.  In a clinical context, they argue 
that long-term treatment,  as  proposed for amelioration  of 
autoimmune diseases, may be a problem because of its poten- 
tial to prevent the normal replacement of B and T  lymphoid 
compartments.  In  an  experimental  context,  our  findings 
provide a means  to produce  a  cohort of T  cell precursors 
arrested at an important control point, which might be very 
useful  in  attempts  to  address  the  many  outstanding  ques- 
tions concerning early thymocyte differentiation. 
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